Dupixent (dupilumab) has been a game-changer for many patients with moderate-to-severe atopic dermatitis, certain types of asthma, chronic rhinosinusitis with nasal polyps, and other inflammatory conditions. But in recent years, doctors, researchers, and plaintiffs’ attorneys have flagged a cluster of serious adverse events that may be connected to the drug. The most notable adverse events are reports of T-cell lymphoma (a form of cutaneous T-cell lymphoma, CTCL).
At Kherkher Garcia, we are aware of the increasing attention Dupixent is receiving. Lawsuits are being filed by patients who have been harmed by this drug. As a result, our team of Houston harmful drug attorneys is exploring potential claims and how our firm can help victims pursue justice.
In the guide below, we explain what Dupixent is, the current state of litigation, and how Kherkher Garcia helps patients who believe they were harmed by a pharmaceutical product.
What is Dupixent and How Does it Work?
Dupixent is the brand name for dupilumab, a biologic therapy developed by Regeneron and Sanofi. It targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathway (key drivers of type 2 inflammation) to reduce symptoms of eczema (atopic dermatitis), certain types of asthma, and other inflammatory diseases. Because it changes immune signaling, it can reduce inflammation where it’s problematic. However, modifying immune pathways can also lead to unintended effects in other tissues.
Reported Adverse Effects Prompting Legal Claims
Two clusters of adverse events have drawn the most attention:
Ocular surface disease (conjunctivitis and keratitis)
Clinical trials and post-marketing reports have consistently shown higher rates of conjunctivitis and keratitis in patients taking Dupixent, particularly among people treated for atopic dermatitis. Many of these cases are mild-to-moderate, but some patients have experienced persistent or severe eye inflammation requiring specialist care. The FDA label documents these risks.
Possible link to T-cell lymphomas (CTCL / peripheral T-cell lymphoma)
A smaller but growing number of case reports and lawsuits allege that Dupixent may have unmasked, accelerated, or contributed to the progression of cutaneous T-cell lymphoma in patients whose early lymphoma resembled or was misdiagnosed as eczema. Plaintiffs contend manufacturers downplayed or failed to adequately warn about this risk. Law firms and mass-tort practices are now actively investigating and filing individual product-liability suits.
Why are People Filing Dupixent Claims Now?
Several factors are driving litigation:
- Accumulation of case reports and patient stories. As more patients use Dupixent, rare but serious events are surfacing. Some patients developed CTCL after starting treatment; in some cases, symptoms were mistaken for worsening eczema while cancer advanced. Regulatory and label attention to ocular risks. The FDA-approved label includes conjunctivitis and keratitis warnings. Plaintiffs argue this wasn’t sufficiently emphasized earlier, or that the manufacturers should have investigated certain cancer signals more deeply.
- Specialized legal investigation. Law firms that focus on pharmaceutical injury are collecting medical records and expert opinions to find patterns that can support product-liability claims alleging failures to warn, negligent design, or inadequate post-market surveillance.
Current State of Litigation
Most cases so far are individual product-liability lawsuits rather than a single consolidated class action. Plaintiffs’ firms are investigating and filing claims in multiple jurisdictions. Some legal sources report increasing filings and at least one wrongful-death complaint tied to alleged lymphoma after Dupixent use.
Courts may consolidate cases into an MDL (multi-district litigation) if enough common factual issues emerge, but as litigation is still developing, each plaintiff’s case is being handled individually at this point. Kherkher Garcia has vast experience with both individual and MDL cases.
Who Might Have a Dupixent Claim?
Potential claimants generally include people who meet one of the following criteria:
- Took Dupixent and subsequently developed serious eye disease (severe/ongoing conjunctivitis or keratitis) that required extended medical treatment or caused lasting harm; or
- Were diagnosed with CTCL or another T-cell lymphoma after starting Dupixent, where medical evidence suggests the drug may have contributed to masking, accelerating, or worsening the cancer.
Eligibility depends on individual medical history, timing of symptoms relative to drug exposure, medical records, and expert medical opinions. A skilled attorney will review each of these elements, and will consult experts when necessary.
Why Kherkher Garcia is Exploring Dupixent Claims
At Kherkher Garcia, we explore claims when there is:
- a plausible medical or scientific link between a drug and harm;
- a pattern of similar injuries emerges across multiple patients;
- or when there may be grounds to allege the manufacturer failed to warn, investigate, or monitor post-market safety appropriately.
Kherkher Garcia has experience handling complex pharmaceutical and product-liability cases. Our attorneys have experience assembling medical experts, reviewing regulatory filings, and managing litigation against large drug manufacturers. Our team evaluates records quickly to determine whether a case merits further investigation and how best to pursue compensation and accountability.
How Kherkher Garcia Helps Victims of Harmful Drugs
If you or a loved one took Dupixent and suffered a serious eye injury or were diagnosed with T-cell lymphoma, Kherkher Garcia can:
- Collect and review medical records, prescription history, and dermatology/oncology notes.
- Work with independent medical experts (dermatologists, oncologists, ophthalmologists) to assess causation and timing.
- Advise on legal options, such as individual lawsuits or potential wrongful-death claims.
- Advise on whether consolidation (MDL) may be appropriate.
- Handle communications with insurers and manufacturers.
- Pursue negotiated settlements when appropriate.
- Litigate aggressively in court when necessary.
Our team understands the medical complexity and emotional weight of these cases. We focus on clear communication, thorough investigation, and compassionate client service every step of the way.
Frequently Asked Questions (FAQ)
Q: Is everyone who took Dupixent at risk of cancer?
A: No. Lawsuits focus on a small number of patients who developed CTCL or related diagnoses after starting treatment. Each situation requires medical review to understand whether the drug may have played a role.
Q: What symptoms should prompt immediate medical attention?
A: New or worsening eye pain, vision changes, persistent redness, light sensitivity, or any rapidly changing skin lesions should prompt urgent medical evaluation, especially if they start after beginning Dupixent.
Q: How long do I have to file a claim?
A: Time limits (statutes of limitations) vary by state and by the type of claim. Preserve medical records and consult an attorney promptly so deadlines aren’t missed. Kherkher Garcia can evaluate your timeline quickly.
Q: Will I have to go to court?
A: Many pharmaceutical cases resolve through negotiation, but some proceed to trial. Your attorney will recommend the best path based on the strength of the evidence and your goals. Most importantly, with Kherkher Garcia, our attorneys are beside you through every step of the legal process.
Q: What evidence is important?
A: Complete medical records (dermatology, ophthalmology, oncology), pathology reports, timelines of symptoms and medications, and any imaging or biopsy results are crucial. Expert medical opinions are often required to link drug exposure to injury.
Have Questions about Dupixent Claims?
If you or a loved one used Dupixent and experienced serious eye problems or were later diagnosed with cutaneous T-cell lymphoma, contact Kherkher Garcia for a free and confidential case review. Our team will assess your situation and advise whether you may have a Dupixent claim and what steps to take next. You don’t pay any fees unless we recover compensation on your behalf.
To get answers or learn more about your rights and Dupixent claims, call us at 713-333-1030. You can also request more information by submitting our online contact form.
Image by Freepik
